Fig. 2From: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension studySELECTED trial profile. Since the duration of SELECTED is over 5 years, based on first patient dosed date of 31 March 2010, no patient had completed the study as of the data cutoff for this manuscript. AE Adverse eventBack to article page